RT Journal Article
SR Electronic
T1 Cardio-Oncology Preclinical Models: A Comprehensive Review
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5355
OP 5364
DO 10.21873/anticanres.15348
VO 41
IS 11
A1 WAFA BOULEFTOUR
A1 BENOITE MERY
A1 ELISE ROWINSKI
A1 CHARLENE RIVIER
A1 ELISABETH DAGUENET
A1 NICOLAS MAGNE
YR 2021
UL http://ar.iiarjournals.org/content/41/11/5355.abstract
AB Cardiotoxicity is a common side effect induced by cancer therapies, which increases the risk of long-term morbidity and mortality in cancer survivors. To date, the mechanism leading to this toxicity is still unclear, thus complicating cardiac safety assessment and predictive factor identification. The advances in technology, particularly regarding radiation therapy and constant development of novel antineoplastic agents, require urgent development of efficient preclinical models to detect drug cardiotoxicity. A myriad of empirical preclinical models have been used to investigate cardiotoxicity, though with limited success. Recently, multicellular spheroid models have gained attention by mimicking the in vivo microenvironment. The aim of this review is to focus on the most relevant preclinical models used to assess antineoplastic drug- and radiotherapy-related cardiotoxicities, with an overview on their current use. It also aims to discuss the possible directions of translational research in the cardio-oncology field.